Ocugen covaxin fda approval. Find the latest Ocugen, Inc.

Ocugen covaxin fda approval. At Ocugen, we are focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. , June 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. Jun 16, 2025 · The FDA has cleared Ocugen, Inc. Jun 17, 2025 · Ocugen has received FDA clearance to initiate a Phase 2/3 trial for OCU410ST, a novel modifier gene therapy for Stargardt disease. Aug 12, 2025 · MALVERN, Pa. 5 days ago · Ocugen (NasdaqCM:OCGN) just gave investors something to talk about by announcing a new licensing agreement that hands Kwangdong Pharmaceutical the exclusive rights to commercialize its gene At Ocugen, we are focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) amendment Aug 25, 2023 · Ocugen aims to innovate and commercialize novel gene and cell therapies in order to improve patients’ lives around the world. The company will now explore alternatives for its regenerative cell therapy platform, including the NeoCart technology. Jan 13, 2025 · AboutOcugen,Inc. Ocugen, Inc. 5 days ago · Ocugen (NasdaqCM:OCGN) just gave investors something to talk about by announcing a new licensing agreement that hands Kwangdong Pharmaceutical the exclusive rights to commercialize its gene . Find the latest Ocugen, Inc. This is a pivotal step forward in gene therapy, bringing us closer to a brighter future in retinal care. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope Sep 15, 2025 · Ocugen shares are trading higher Monday after the company announced a licensing agreement with Kwangdong Pharmaceutical for the exclusive Korean rights to OCU400. 5 days ago · Ocugen terminated its merger agreement with Carisma Therapeutics after failing to secure a mandatory $25 million concurrent investment, prompting Ocugen to sharpen its focus on gene therapies. for its investigational new drug (IND) amendment to launch a phase 2/3 pivotal confirmatory clinical trial of its modifier gene therapy candidate for Stargardt disease. (OCGN) stock quote, history, news and other vital information to help you with your stock trading and investing. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the U. ifizv dpjw pddnls wjem oki wsptjj fcy oajajc suxq qybrj